{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:08:11Z","timestamp":1759190891599,"version":"3.44.0"},"reference-count":22,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Pulmonary infections caused by Mycobacterium avium complex (MAC) are notoriously difficult to treat, particularly in the context of multidrug resistance. Immunotherapy with checkpoint inhibitors, though effective in various malignancies, has uncertain immunomodulatory effects on chronic infections such as MAC. Case Summary: We report a case of a 67-year-old man with at least a 6-year history of treatment refractory MAC who developed stage IIIB mismatch repair-deficient colon adenocarcinoma. Despite years of multidrug therapy, the patient had persistent positive acid-fast bacilli cultures. Upon initiation of pembrolizumab for colon cancer, with no concurrent anti-MAC therapy, he experienced radiologic and microbiologic improvement. Following subsequent reinitiation of multidrug MAC therapy, he achieved his first documented negative culture after over a decade of infection and has remained culture-negative and in cancer remission for over two years. Conclusions: This case suggests that immune checkpoint inhibitors like pembrolizumab may enhance antimicrobial immune responses against MAC through PD-1 pathway modulation. The temporal association between pembrolizumab therapy and MAC clearance warrants further investigation into immunomodulatory approaches for drug-resistant mycobacterial infections, particularly as adjunctive therapy to conventional antimicrobial regimens.<\/jats:p>","DOI":"10.3390\/ph18101464","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T10:49:34Z","timestamp":1759142974000},"page":"1464","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microbial Clearance of Refractory Mycobacterium avium Complex Pulmonary Disease During Pembrolizumab and Intensified Antimicrobial Therapy: A Case Report"],"prefix":"10.3390","volume":"18","author":[{"given":"Jan Naseer","family":"Kaur","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9888-1595","authenticated-orcid":false,"given":"Parikshit","family":"Padhi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhani","family":"Pal","sequence":"additional","affiliation":[{"name":"Nichols School, Buffalo, Buffalo, NY 14216, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12931-019-1258-9","article-title":"Clinical characteristics and treatment outcomes of patients with macrolide-resistant complex pulmonary disease: A systematic review and meta-analysis","volume":"20","author":"Park","year":"2019","journal-title":"Respir. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106025","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"210212","DOI":"10.1183\/16000617.0212-2021","article-title":"Management of complex and pulmonary disease: Therapeutic advances and emerging treatments","volume":"31","author":"Kumar","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e01798-16","DOI":"10.1128\/AAC.01798-16","article-title":"In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex","volume":"61","author":"Philley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/14787210.6.3.351","article-title":"Mycobacterium avium complex infection in HIV\/AIDS patients","volume":"6","author":"Corti","year":"2008","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1086\/515687","article-title":"Enhanced induction of interleukin-12(p40) secretion by human macrophages infected with Mycobacterium avium complex isolates from disseminated infection in AIDS patients","volume":"178","author":"Plum","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0732-8893(99)00005-X","article-title":"Immunological defense mechanisms in tuberculosis and mac-infection","volume":"34","author":"Hartmann","year":"1999","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.chom.2017.05.012","article-title":"Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis","volume":"21","author":"Moguche","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/JLB.3CE0520-104R","article-title":"Mycobacterial immunevasion\u2014Spotlight on the enemy within","volume":"109","author":"Henneke","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.tube.2018.03.001","article-title":"Interleukin 23\/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease","volume":"110","author":"Shu","year":"2018","journal-title":"Tuberculosis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"52668","DOI":"10.7554\/eLife.52668","article-title":"Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1","volume":"9","author":"Tezera","year":"2020","journal-title":"eLife"},{"key":"ref_16","first-page":"20499361251339300","article-title":"Recombinant interleukin-7 treatment of refractory Mycobacterium avium complex lung disease (IMPULSE-7): A pilot phase II, single-center, randomized, clinical trial","volume":"12","author":"Spec","year":"2025","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lin, S., Hua, W., Wang, S., Zhang, Y., Chen, X., Liu, H., Shao, L., Chen, J., and Zhang, W. (2022). In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates. BMC Microbiol., 22.","DOI":"10.1186\/s12866-022-02582-2"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria","volume":"74","author":"Ruth","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","article-title":"Microbiology and Preclinical Review of Omadacycline","volume":"69","author":"Karlowsky","year":"2019","journal-title":"Clin Infect Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5588\/ijtldopen.25.0152","article-title":"Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy","volume":"2","author":"Kuksa","year":"2025","journal-title":"IJTLD Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","article-title":"Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: Current evidence and clinical practice recommendations","volume":"7","author":"Anastasopoulou","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: An old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/10\/1464\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:02:39Z","timestamp":1759143759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/10\/1464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ph18101464"],"URL":"https:\/\/doi.org\/10.3390\/ph18101464","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}